Janux Therapeutics (JANX) EBIT Margin (2021 - 2025)
Historic EBIT Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 352.51%.
- Janux Therapeutics' EBIT Margin rose 78119500.0% to 352.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 1442.88%, marking a year-over-year decrease of 7841200.0%. This contributed to the annual value of 933.58% for FY2024, which is 307100.0% down from last year.
- As of Q3 2025, Janux Therapeutics' EBIT Margin stood at 352.51%, which was up 78119500.0% from 8164.46% recorded in Q3 2024.
- In the past 5 years, Janux Therapeutics' EBIT Margin registered a high of 155.36% during Q2 2024, and its lowest value of 8164.46% during Q3 2024.
- For the 5-year period, Janux Therapeutics' EBIT Margin averaged around 1338.23%, with its median value being 843.51% (2021).
- As far as peak fluctuations go, Janux Therapeutics' EBIT Margin crashed by -75362200bps in 2024, and later soared by 78119500bps in 2025.
- Janux Therapeutics' EBIT Margin (Quarter) stood at 834.78% in 2021, then rose by 23bps to 642.04% in 2022, then dropped by -2bps to 655.71% in 2023, then tumbled by -1145bps to 8164.46% in 2024, then soared by 96bps to 352.51% in 2025.
- Its EBIT Margin was 352.51% in Q3 2025, compared to 8164.46% in Q3 2024 and 155.36% in Q2 2024.